Capalbo Donatella, Mattace Raso Giuseppina, Esposito Andrea, Di Mase Raffaella, Barbieri Flavia, Meli Rosaria, Bruzzese Dario, Salerno Mariacarolina
Pediatric Endocrinology Unit, Department of Translational Medical Sciences, University "Federico II" of Naples, Naples, Italy.
Clin Endocrinol (Oxf). 2014 Jun;80(6):856-62. doi: 10.1111/cen.12393. Epub 2014 Jan 16.
Growth hormone (GH) deficiency (GHD) in adults is associated with increased cardiovascular (CV) risk. Although some authors have documented the presence of early CV risk factors in untreated GHD children, results are still inconsistent. Aim of this study was to evaluate the effects of GHD and GH therapy on early cardiometabolic risk factors in a large cohort of children.
Waist-to-height ratio (WHtR), triglycerides, total-, low-density lipoprotein (LDL), high-density lipoprotein (HDL) cholesterol, atherogenic index (AI = total /HDL cholesterol), homocysteine, leptin, adiponectin, high-sensitivity C-reactive protein (hsCRP) and fibrinogen were evaluated in seventy-one GHD children (9·8 ± 3·6 years) before and after 2 years of GH therapy. Seventy-one healthy controls comparable with patients for age, sex and body mass index (BMI) were enrolled.
Compared with controls, GHD children at study entry had higher WHtR (0·52 ± 0·05 vs 0·45 ± 0·19, P = 0·004), triglycerides (0·44 ± 0·98 vs -0·03 ± 0·73 SDS, P = 0·012), total cholesterol (0·28 ± 1·08 vs -0·46 ± 0·98 SDS, P < 0·001), LDL cholesterol (0·20 ± 0·90 vs -0·39 ± 1·06 SDS, P = 0·007), AI (3·19 ± 0·73 vs 2·77 ± 0·53, P = 0·001), homocysteine (8·45 ± 1·8 vs 7·72 ± 1·6 μm, P = 0·003), leptin (8·03 ± 4·2 vs 5·09 ± 1·9 ng/ml, P = 0·001) and fibrinogen (292·6 ± 33 vs 268 ± 31·4 mg/dl, P = 0·011). No differences were found in adiponectin or hsCRP. GH therapy was associated with a significant reduction in WHtR (P < 0·001), total cholesterol (P < 0·001), LDL cholesterol (P = 0·002), homocysteine (P = 0·044) leptin (P = 0·022) and fibrinogen (P = 0·001). Moreover, GH therapy was associated with a significant increase in adiponectin levels (P = 0·001).
Our data suggest that children with untreated GHD exhibit a cluster of early cardiovascular risk factors and that GH treatment exerts beneficial effects on these abnormalities.
成人生长激素(GH)缺乏(GHD)与心血管(CV)风险增加相关。尽管一些作者已证明未经治疗的GHD儿童存在早期CV危险因素,但其结果仍不一致。本研究的目的是评估GHD和GH治疗对一大群儿童早期心脏代谢危险因素的影响。
对71例GHD儿童(9.8±3.6岁)在GH治疗2年前后进行腰高比(WHtR)、甘油三酯、总胆固醇、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)胆固醇、致动脉粥样硬化指数(AI = 总胆固醇/HDL胆固醇)、同型半胱氨酸、瘦素、脂联素、高敏C反应蛋白(hsCRP)和纤维蛋白原的评估。纳入71名年龄、性别和体重指数(BMI)与患者匹配的健康对照。
与对照组相比,研究开始时GHD儿童的WHtR更高(0.52±0.05 vs 0.45±0.19,P = 0.004)、甘油三酯更高(0.44±0.98 vs -0.03±0.73 SDS,P = 0.012)、总胆固醇更高(0.28±1.08 vs -0.46±0.98 SDS,P < 0.001)、LDL胆固醇更高(0.20±0.90 vs -0.39±1.06 SDS,P = 0.007)、AI更高(3.19±0.73 vs 2.77±0.53,P = 0.001)、同型半胱氨酸更高(8.45±1.8 vs 7.72±1.6 μmol,P = 0.003)、瘦素更高(8.03±4.2 vs 5.09±1.9 ng/ml,P = 0.001)和纤维蛋白原更高(292.6±33 vs 268±31.4 mg/dl,P = 0.011)。脂联素或hsCRP无差异。GH治疗与WHtR(P < 0.001)、总胆固醇(P < 0.001)、LDL胆固醇(P = 0.002)、同型半胱氨酸(P = 0.044)、瘦素(P = 0.022)和纤维蛋白原(P = 0.001)的显著降低相关。此外,GH治疗与脂联素水平的显著升高相关(P = 0.001)。
我们的数据表明,未经治疗的GHD儿童表现出一系列早期心血管危险因素,且GH治疗对这些异常具有有益作用。